Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07682610 · ClinicalTrials.gov registry record · NA
Kentucky - Quality Improvement Implementation Lung Cancer Screening (QUILS™) Health Services Research Intervention
A NA study, sponsored by Timothy Mullett.
- Recruiting
- Registry status
- NA
- Development phase
- 35,500
- Enrollment target
NCT07682610: Recruiting NA study, sponsored by Timothy Mullett.
NCT07682610 is a NA study that is actively recruiting participants, run by Timothy Mullett. The registered enrollment target is 35,500 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2430% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07682610, a NA study, is actively recruiting participants, sponsored by Timothy Mullett.
- RECRUITING
- Registry status
- NA
- Development phase
- 35,500 participants
- Enrollment target
Study Summary
This clinical trial studies statewide optimization of lung cancer screening (LCS) in Kentucky using the Quality Implementation of Lung Screening (QUILS™) System. Data from the Kentucky Cancer Registry shows that LCS implementation has contributed to a rapid decline in late-stage lung cancer diagnosis at twice the national average. Further, the declines are more than three times the national average decline in Kentucky's Central Appalachian region. Kentucky-based multilevel initiatives are needed to expand and accelerate this leading role and extend the LCS opportunity to more Kentuckians who are at increased risk of lung cancer. This trial may be able to accelerate optimal high-quality implementation of LCS utilizing the QUILS™ System and reduce the burden of lung cancer by assisting lung cancer screening programs located throughout Kentucky in implementing best practices in lung cancer screening by integrating the QUILS™ System domains and elements into their screening programs.
Primary Outcome
The QUILS Index Assessment is a program-level measure of lung cancer screening implementation quality. Scores range from 0 to 95, with a higher score indicating higher quality implementation of lung cancer screening practices. The outcome measure is the change in total QUILS Index score from Baseline to 12 months.
Interventions
- BEHAVIORAL Quality Implementation of Lung Cancer Screening (QUILS) System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,500 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2028-06-01 |
| Phase | NA |
What NCT07682610 shows while recruiting
NCT07682610 is an interventional study that assigns participants to a tested intervention. Its 35,500 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2430% higher).
The record links to 0 conditions, and to 1 intervention - of which Quality Implementation of Lung Cancer Screening (QUILS) System is the first listed.
NCT07682610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07682610 about?
NCT07682610 is a clinical study titled "Kentucky - Quality Improvement Implementation Lung Cancer Screening (QUILS™) Health Services Research Intervention". This clinical trial studies statewide optimization of lung cancer screening (LCS) in Kentucky using the Quality Implementation of Lung Screening (QUILS™) System. Data from the Kentucky Cancer Registry shows that LCS implementation has contributed to a rapid decline in late-stage lung cancer diagnosi...
What is the current status of trial NCT07682610?
This trial is currently recruiting. It is a NA study. The enrollment target is 35,500 participants. The study started on 2025-04-01. Estimated completion is 2028-06-01.
What interventions are being tested in trial NCT07682610?
The interventions under investigation include: Quality Implementation of Lung Cancer Screening (QUILS) System (BEHAVIORAL).
Who is sponsoring clinical trial NCT07682610?
This trial is sponsored by Timothy Mullett, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07682610's enrollment target sits among peer trials
35,500 7th of 2000 higher than 1,994 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI